Johnson & Johnson vs AbbVie: Safe Dividend vs Higher Yield

The article compares Johnson & Johnson (J&J) and AbbVie as investment options, focusing on their dividend characteristics and business strategies. J&J offers a safer, more diversified dividend with a 64-year streak and an AAA-rated balance sheet, while AbbVie provides a higher yield but carries more single-product risk, despite its aggressive M&A strategy and strong immunology franchise. The author recommends J&J for income investors seeking safety and AbbVie for those pursuing total return with a higher risk tolerance.